Rituximab and Ocrelizumab levels in Multiple Sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial looks at two medicines, rituximab and ocrelizumab, in the blood of people with multiple sclerosis. It only includes people who are already in another study called OVERLORD-MS and can give blood samples on a schedule.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are already part of the OVERLORD-MS study.
- You agree to come to the lab for blood draws at scheduled times.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares rituximab and ocrelizumab in people with relapsing-remitting multiple sclerosis (MS) to see which medicine better controls MS activity. It may help reduce future relapses and new MRI lesions.
This study looks at how well the injected form of ocrelizumab works for people with relapsing-remitting multiple sclerosis (RRMS) in everyday care. It aims to understand the treatment's effects and side effects outside of a clinical trial setting.
This trial tests an injectable medication called ocrelizumab for children and teenagers with relapsing-remitting multiple sclerosis. The goal is to see if it is safe and how well it works to control the disease.
This trial tests whether treating relapsing multiple sclerosis (RRMS) aggressively and early with a specific medication can slow disease progression. You may qualify if you were recently diagnosed, have had recent disease activity, and are willing to take a strong immunosuppressive drug with regular MRI monitoring.
This Phase 3 trial compares two similar immune therapies—rituximab and ocrelizumab—to see if rituximab works about as well for relapsing multiple sclerosis. It may help you and researchers understand which option is equally effective and safe for preventing relapses and disease activity.
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
Hear when a new Relapsing Remitting Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.